Mitzi Washington, MD
Pediatrics · Searcy, ARNPI 1114909124
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $367 and has fallen 80.9% since, to $70 in 2025.
Across 72 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$182
- Pfizer$138
- Genentech USA, Inc.$124
- Abbott$117
- Sanofi Pasteur Inc.$109
- AstraZeneca$105
- plus $504 from 13 others
Across 4 payments — averaging $1470.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6K
What the payments were for
- Food & beverage$1,279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 11 | $182 |
| Pfizer | 7 | $138 |
| Genentech USA, Inc. | 4 | $124 |
| Abbott | 5 | $117 |
| Sanofi Pasteur Inc. | 7 | $109 |
| AstraZeneca(2 entities) | 8 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Merck | 6 | $87 |
| GSK | 3 | $62 |
| Tris Pharma Inc | 3 | $61 |
| Supernus Pharmaceuticals, Inc. | 4 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Seqirus USA Inc | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Sanofi | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| Boehringer Ingelheim | 1 | $11 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$1,279 in reported general payments places this provider in the 85th percentile of 464 pediatrics providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,392 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 30 | $6,153 |
| FarxigaDapagliflozin Propanediol | 11 | $5,664 |
| Chlorpromazine Hcl | 12 | $4,746 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $2,485 |
| Novolin NInsulin Nph Human Isophane | 13 | $2,083 |
| Mycophenolate Mofetil | 11 | $1,107 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $980 |
| Gabapentin | 47 | $595 |
| Atorvastatin Calcium | 71 | $595 |
| Duloxetine Hcl | 32 | $582 |
| Sucralfate | 16 | $555 |
| SynthroidLevothyroxine Sodium | 12 | $538 |
| Pantoprazole Sodium | 56 | $472 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 20 | $463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix | $62 | $6,15330 claims |
| AstraZenecaFarxiga | $105 | $5,66411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 464 pediatrics providers in Arkansas.
Other pediatrics in Searcy
- Howard OrsburnRussellville$71K
- David GoodmanWest Memphis$61K
- Robert PesekLittle Rock$20K
- Peyton MillsLittle Rock$7K
- Rachel WhiteJacksonville$5K
- Eduardo OchoaLittle Rock$4K
- Laura MarrattLittle Rock$4K
- Jane MiersSherwood$4K
- Jennifer JohnsonFort Smith$4K
- Ashley DavisSherwood$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.